“A new paradigm for treating metabolic diseases.”
ABOUT US
Eternygen is a Berlin based start up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen’s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseases with dramatically increasing prevalences in the last decades. Eternygen’s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes and obesity.
Company’s emphasis is the development of a safe and effective drug for treatment of these widespread diseases via targeted adjustment of underlying metabolic failure.
RESEARCH & DEVELOPMENT
LITERATUR & PAPER
Willmes et al. 2021 – JCI Insight.
The longevity gene mIndy (I’m Not Dead, Yet) affects blood pressure through sympathoadrenal mechanisms
Wagner et al. 2021 – Nature Medicine
Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes
Henke et al. 2020 – Neurobiol Dis
Disruption of the sodium-dependent citrate transporter SLC13A5 in mice causes alterations in brain citrate levels and neuronal network excitability in the hippocampus
Schumann et al. 2020 – Pharmacology Review
Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease
OUR TEAM
Partners & Collaborators
